Science
The Indian Express

India’s bird flu fight gets a homegrown weapon: First indigenous vaccine against H5N1 developed

Source Entity

Anand Mohan J

November 22, 2026
India’s bird flu fight gets a homegrown weapon: First indigenous vaccine against H5N1 developed

India has unveiled its first indigenous vaccine against the H5N1 bird flu strain, developed by ICAR-NIHSAD. Priced at just ₹1-2 per dose, this innovation aims to secure the poultry industry and minimize economic losses for farmers.

A Milestone in Indian Veterinary Science

In a significant leap for domestic animal health research, India has officially unveiled its first indigenous vaccine designed to combat the H5N1 strain of avian influenza. Developed by the Bhopal-based National Institute of High Security Animal Diseases (NIHSAD) under the Indian Council of Agricultural Research (ICAR), this breakthrough represents a major stride toward national self-reliance in veterinary medicine. The vaccine was formally dedicated to the nation by Union Agriculture Minister Shivraj Singh Chouhan, marking a pivotal shift in how the country addresses the recurring threat of highly pathogenic avian influenza.

Economic Resilience for Rural Farmers

For the Indian agricultural sector, the poultry industry serves as a vital economic pillar. Minister Shivraj Singh Chouhan aptly described livestock as "moving ATMs" for rural households, highlighting their role in providing consistent income. By mitigating the threat of H5N1, which has historically caused mass mortality in chicken populations and subsequent financial devastation for poultry farmers, this vaccine acts as a critical insurance policy for rural livelihoods. The affordability of the vaccine, priced at a modest ₹1–2 per dose, ensures that even small-scale farmers can access protection, thereby stabilizing the rural economy against disease-driven volatility.

Strengthening National Biosecurity

Beyond immediate economic benefits, the development of this vaccine enhances India’s broader biosecurity infrastructure. The H5N1 virus is a highly pathogenic strain capable of spreading rapidly through poultry populations, causing significant disruptions to food supply chains and domestic consumption markets. By localizing the production of an effective vaccine, India reduces its dependence on imported solutions and gains the ability to respond more agilely to localized outbreaks. This technological independence is a cornerstone of the government's push toward Atmanirbhar Bharat (Self-Reliant India) in the scientific and agricultural domains.

Investment in Research Infrastructure

Alongside the vaccine launch, the announcement of a new ₹300-crore state-of-the-art animal disease research laboratory underscores the government's commitment to long-term scientific preparedness. This facility is expected to bolster the capabilities of NIHSAD, allowing for more advanced genomic studies and faster development of vaccines for other emerging animal pathogens. Such investments are essential for maintaining a robust surveillance network capable of detecting and containing zoonotic diseases before they escalate into larger crises.

Future Implications and Trends

Looking forward, the successful deployment of this indigenous vaccine is expected to transform the poultry industry's risk management strategies. As climate patterns shift and human-wildlife interaction increases, the risk of avian influenza outbreaks remains a persistent global challenge. India’s proactive focus on vaccine development positions it as a leader in the region’s animal health sector. Moving forward, the focus will likely shift toward widespread distribution and the development of vaccination protocols that can be seamlessly integrated into existing agricultural practices, ensuring a safer and more resilient future for India’s poultry farmers.

Verification Required?

Read the full report from the primary source

Go to The Indian Express